{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:21:46Z","timestamp":1761578506578},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,7,6]],"date-time":"2004-07-06T00:00:00Z","timestamp":1089072000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1038\/sj.bjc.6602010","type":"journal-article","created":{"date-parts":[[2004,7,7]],"date-time":"2004-07-07T01:36:19Z","timestamp":1089164179000},"page":"482-488","source":"Crossref","is-referenced-by-count":54,"title":["Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study"],"prefix":"10.1038","volume":"91","author":[{"name":"for the Lung Cancer Committee of the Hellenic Oncology Research Group (HORG)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Georgoulias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Kouroussis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Agelidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Boukovinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Palamidas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Stavrinidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Syrigos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Veslemes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Toubis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Ardavanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Tselepatiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Vlachonikolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,7,6]]},"reference":[{"key":"BF6602010_CR1","unstructured":"American Society of Clinical Oncology (1997) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 15: 2996\u20133018"},{"key":"BF6602010_CR2","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1023\/A:1008497322508","volume":"9","author":"N Androulakis","year":"1998","unstructured":"Androulakis N, Kouroussis Ch, Kakolyris S, Tzannes S, Papadakis E, Papadimitriou C, Geroyianni A, Georgopoulou T, Dimopoulou I, Souglakos J, Kotsakis A, Vardakis N, Hatzidaki D, Georgoulias V (1998) Salvage treatment with paclitaxel and gemcitabine for patients with non-small cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study. Ann Oncol 9: 1127\u20131130","journal-title":"Ann Oncol"},{"key":"BF6602010_CR3","first-page":"494a","volume":"18","author":"N Androulakis","year":"1999","unstructured":"Androulakis N, Papadakis E, Bania E, Apostolopulou F, Tsiafaki X, Kalofonos C, Rapti A, Toubis M, Chainis K, Kouroussis Ch, Sarra E, Vardakis N, Hatzidaki D, Georgoulias V (1999) Second-line treatment with docetaxel (D) and gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II trial. Proc Am Soc Clin Oncol 18: 494a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602010_CR4","first-page":"495a","volume":"18","author":"P Baas","year":"1999","unstructured":"Baas P, Cordington H, Muller M, Dalesio O, Kwa Van HB, Zandwijk N (1999) Second-line gemcitabine (G) therapy in non-small cell lung cancer (NSCLC) stage IIIb and IV. Proc Am Soc Clin Oncol 18: 495a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602010_CR5","first-page":"302","volume":"20","author":"CP Belani","year":"1993","unstructured":"Belani CP (1993) Multimodality management of regionally advanced non-small cell lung cancer. Semin Oncol 20: 302\u2013314","journal-title":"Semin Oncol"},{"key":"BF6602010_CR6","volume-title":"Modeling Survival Data in Medical Research","author":"D Collet","year":"1999","unstructured":"Collet D (1999) Modeling Survival Data in Medical Research. London, UK: Chapman & Hall"},{"key":"BF6602010_CR7","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1200\/JCO.1999.17.7.2081","volume":"17","author":"L Crino","year":"1999","unstructured":"Crino L, Mosconi AM, Scagliotti GV, Selvaggi G, Novello S, Rinaldi M, Della Giulia M, Gridelli C, Rossi A, Calandri C, De Marinis F, Noseda M, Tonato M (1999) Gemcitabine as second-line treatment for advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 17: 2081\u20132085","journal-title":"J Clin Oncol"},{"key":"BF6602010_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0169-5002(00)00112-4","volume":"29","author":"D Ferrigno","year":"2000","unstructured":"Ferrigno D, Buccheri G (2000) Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? Lung Cancer 29: 91\u2013104","journal-title":"Lung Cancer"},{"key":"BF6602010_CR9","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","volume":"18","author":"FV Fossella","year":"2000","unstructured":"Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18: 2354\u20132362","journal-title":"J Clin Oncol"},{"key":"BF6602010_CR10","first-page":"455","volume":"24","author":"FV Fossella","year":"1997","unstructured":"Fossella FV, Lee JS, Hong WK (1997) Management strategies for recurrent non-small cell lung cancer. Semin Oncol 24: 455\u2013462","journal-title":"Semin Oncol"},{"key":"BF6602010_CR11","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","volume":"21","author":"FV Fossella","year":"2003","unstructured":"Fossella FV, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kankel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016\u20133024","journal-title":"J Clin Oncol"},{"key":"BF6602010_CR12","first-page":"462a","volume":"18","author":"RS Herbst","year":"1999","unstructured":"Herbst RS, Khuri FR, Jung M, Fossella FV, Lee JS, Glisson B, Shin DM, Pisters K, Papadimitrakopoulou V, Kurie J, Perez-Soler R, Liu D, Munden R, Hong WK (1999) Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. Proc Am Soc Clin Oncol 18: 462a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602010_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0169-5002(99)00092-6","volume":"27","author":"CC Herrero","year":"2000","unstructured":"Herrero CC, Martinez EN, Jaime AB (2000) Second-line treatment with gemcitabine and vinorelbine in non-small cell lung cancer cisplatin failures: a pilot study. Lung Cancer 27: 47\u201353","journal-title":"Lung Cancer"},{"issue":"Suppl 1","key":"BF6602010_CR14","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/S0959-8049(05)80262-X","volume":"29A","author":"PJ Hollen","year":"1993","unstructured":"Hollen PJ, Gralla RJ, Kris MG, Potanovich LM (1993) Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 29A (Suppl 1): S51\u2013S58","journal-title":"Eur J Cancer"},{"key":"BF6602010_CR15","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1200\/JCO.2000.18.21.3722","volume":"18","author":"C Huisman","year":"2000","unstructured":"Huisman C, Smit EFR, Giaccone G, Postmus PE (2000) Second-line chemotherapy in relapsing or refractory non-small cell lung cancer: a review. J Clin Oncol 18: 3722\u20133730","journal-title":"J Clin Oncol"},{"key":"BF6602010_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0169-5002(00)00144-6","volume":"30","author":"RV Iaffaioli","year":"2000","unstructured":"Iaffaioli RV, Tortoriello A, Gravina A, Facchini G, Turitto G, Elia S, Griffo S, Gentile M, Fraioli G, Frattolillo A, Muto P, Libutti M, De Marino V, Illiano A, Barbarisi A (2000) Phase I\u2013II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB\u2013IV non-small cell lung cancer. Lung Cancer 30: 203\u2013210","journal-title":"Lung Cancer"},{"key":"BF6602010_CR17","first-page":"1891","volume":"22","author":"S Kakolyris","year":"2002","unstructured":"Kakolyris S, Souglakos J, Kouroussis Ch, Koukourakis M, Kalbakis K, Mavroudis D, Vardakis N, Georgoulias V (2002) A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with cisplatin-based front-line chemotherapy. Anticancer Res 22: 1891\u20131896","journal-title":"Anticancer Res"},{"key":"BF6602010_CR18","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S0959-8049(00)00419-6","volume":"37","author":"C Kosmas","year":"2001","unstructured":"Kosmas C, Tsavaris N, Panopoulos C, Vadiaka M, Stavroyianni N, Kourelis T, Malamos N, Antonopoulos M, Kalofonos HP (2001) Gemcitabine and vinorelbine as second-line therapy in non-small cell lung cancer after prior treatment with taxane+platinum-based regimens. Eur J Cancer 37: 972\u2013978","journal-title":"Eur J Cancer"},{"key":"BF6602010_CR19","first-page":"5944","volume":"47","author":"T Kunimoto","year":"1987","unstructured":"Kunimoto T, Nitta K, Kanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10[4-(1-piperidino)-1-piperidino]-1-carbonyloxy-camptothecin, a novel water soluble derivative of amptothecin, against murine tumors. Cancer Res 47: 5944\u20135947","journal-title":"Cancer Res"},{"key":"BF6602010_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0169-5002(01)00477-9","volume":"36","author":"E Laack","year":"2002","unstructured":"Laack E, Dierlamm T, Knuffmann C, Popp J, Schmied B, Durk H, Wacker-Backerhaus G, Zeller W, Verpoort K, Fiedler W, Kurt Hossfeld D (2002) Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer. Lung Cancer 36: 303\u2013307","journal-title":"Lung Cancer"},{"key":"BF6602010_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0169-5002(01)00209-4","volume":"34","author":"KM Leu","year":"2001","unstructured":"Leu KM, Kim KM, Larson M, Larson M, Schiller JH (2001) Phase I\/II of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. Lung Cancer 34: 105\u2013113","journal-title":"Lung Cancer"},{"key":"BF6602010_CR22","first-page":"961a","volume":"17","author":"R Lima","year":"1998","unstructured":"Lima R, Peckel JA, Putman-Hair T, Sherman CA, Leong SS, Green MR (1998) Ongoing phase I study of irinotecan (CPT-11) and gemcitabine (GEM). Proc Am Soc Clin Oncol 17: 961a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602010_CR23","doi-asserted-by":"crossref","unstructured":"Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899\u2013909","DOI":"10.1136\/bmj.311.7010.899"},{"key":"BF6602010_CR24","first-page":"674a","volume":"18","author":"E O'Reilly","year":"1999","unstructured":"O'Reilly E, Ilson D, Schwartz G, Tong W, Fata F, Kemeny N, Sherwin K, Sharma S, Kelsen D (1999) A phase I study of combination of gemcitabine (gem) and irinotecan (CPT-11) in patients (pts) with refractory solid tumors. Proc Am Soc Clin Oncol 18: 674a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602010_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00001813-199703000-00003","volume":"8","author":"XH Pei","year":"1997","unstructured":"Pei XH, Nakanishi Y, Takayama K, Bai F, Kawasaki M, Tsuruta N, Mizuno K, Hara N (1997) Effect of CPT-11 in combination with other anticancer agents on lung cancer cells. Anticancer Drug 8: 1\u20137","journal-title":"Anticancer Drug"},{"key":"BF6602010_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33: 337\u2013343","journal-title":"Ann Med"},{"key":"BF6602010_CR27","first-page":"521a","volume":"18","author":"GR Reddy","year":"1999","unstructured":"Reddy GR, Gandara DR, Edelman MJ, Doroshow JH, Lau D, Lenz H, Israel V, Albain K, Jaslowski A, Lauder I, Conklin T, Maryon T (1999) Gemcitabine (GEM) in platinum (PLAT) treated non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 18: 521a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602010_CR28","first-page":"484a","volume":"18","author":"A Rossi","year":"1999","unstructured":"Rossi A, Perrone F, Barletta E, Tambaro R, Barzelloni M, Scognamiglio F, Gatani T, Bilancia D, Maiorino L, Gridelli C (1999) Activity of gemcitabine (GEM) in cisplatin-pretreated patients with advanced non-small cell lung cancer (NSCLC): a phase 2 trial. Proc Am Soc Clin Oncol 18: 484a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602010_CR29","first-page":"2143a","volume":"20","author":"CM Schwartz","year":"2001","unstructured":"Schwartz CM, Zhou GZ, Szrajer L, Kurbacher CM, Bruckner H (2001) Evaluation of gemcitabine and irinotecan (CPT-11) as single agents and in combination in solid tumors using an ex\u2013in vitro ATP assay. Proc Am Soc Clin Ocol 20: 2143a","journal-title":"Proc Am Soc Clin Ocol"},{"key":"BF6602010_CR30","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","volume":"18","author":"FA Shepherd","year":"2000","unstructured":"Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095\u20132103","journal-title":"J Clin Oncol"},{"issue":"1 Suppl 2","key":"BF6602010_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0093-7754(01)90297-0","volume":"28","author":"FA Shepherd","year":"2001","unstructured":"Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG (2001) Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin Oncol 28 (1 Suppl 2): 4\u20139","journal-title":"Semin Oncol"},{"key":"BF6602010_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3109\/07357909909021419","volume":"17","author":"MA Socinski","year":"1999","unstructured":"Socinski MA, Steagall A, Gillenwater H (1999) Second-line chemotherapy with 96\u2009h infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial. Cancer Invest 17: 181\u2013188","journal-title":"Cancer Invest"},{"key":"BF6602010_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0140-6736(93)91882-M","volume":"342","author":"PJ Souquet","year":"1993","unstructured":"Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E (1993) Polychemotherapy in advanced non-small cell lung cancer. Lancet 342: 19\u201321","journal-title":"Lancet"},{"key":"BF6602010_CR34","first-page":"71","volume":"21","author":"T Tsuruo","year":"1998","unstructured":"Tsuruo T, Matsuzaki T, Matsusita M, Saito H, Yokokura T (1998) Antitumour effect of CPT-11, a new derivative of camptothecin against pleiotropic drug-resistant tumours in vitro and in vivo. Cancer Chemoth Pharmacol 21: 71\u201374","journal-title":"Cancer Chemoth Pharmacol"},{"key":"BF6602010_CR35","unstructured":"World Health Organization (1979) WHO handbook of reporting results of cancer treatment. WHO Offset, Publication no. 48 Geneva, Switzerland: World Health Organization"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602010","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:10:39Z","timestamp":1684411839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["BF6602010"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602010","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2004,7,6]]}}}